CareRx Corporation
TSX:CRRX.TOMedical - Care Facilities
+$0.02 today
- Market cap
- $203.06M
- Beta
- 0.62
- P/E (TTM)
- 7.4
- EPS (TTM)
- $0.43
- Dividend yield
- 1.88%
Volume 0.01M
Average 0.04M
CRRX.TO Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
CareRx CorporationTSX: CRRX.TO
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 25.4%
Gross margin was 25.4% in Q1 FY2026, down 4.3 pp from a year earlier. On a trailing-twelve-month basis it was 26.5%, down 3.1 pp year over year. Over 3 fiscal years it narrowed by 3.8 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 25.0%
- Year-over-year change
- -4.4pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.0% | -4.4pp |
| FY2024 | 2024-12-31 | 29.5% | +6.6pp |
| FY2023 | 2023-12-31 | 22.9% | -5.9pp |
| FY2022 | 2022-12-31 | 28.8% | +0.1pp |
| FY2021 | 2021-12-31 | 28.7% | — |
Gross Margin vs competitors
How CRRX.TO compares with its peers on the latest reported figures
- CRRX.TO's LTM Mar 2026 gross margin of 26.5% is the lowest of the 5 companies compared; the peer median is 54.6%.
- Its year-over-year change of -3.1 pp is the 2nd highest of 5, against a peer median of -13.5 pp.
- Over three fiscal years its change of -3.8 pp compares with a peer median of -1.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
PRN.TOProfound Medical Corp. | LTM Mar 2026 | 71.0% | +4.1 pp | +25.6 pp |
| LTM Mar 2026 | 61.7% | -21.3 pp | -49.4 pp | |
| LTM Mar 2026 | 47.5% | -5.8 pp | +39.8 pp | |
| LTM Mar 2026 | 44.5% | -21.3 pp | -28.1 pp | |
| LTM Mar 2026 | 26.5% | -3.1 pp | -3.8 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding CRRX.TO) | 54.6% | -13.5 pp | -1.3 pp | |
Competitors are the stored peer set for CRRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 262.63M | 381.73M | 370.75M | 366.71M | 370.24M |
| Cost of Revenue | 187.35M | 271.79M | 286.02M | 258.65M | 277.61M |
| Gross Profit | 75.28M | 109.93M | 84.72M | 108.06M | 92.63M |
| Gross Margin | 28.7% | 28.8% | 22.9% | 29.5% | 25.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 70.52M | 102.55M | 77.5M | 32.75M | 34.23M |
| Operating Expenses | 70.47M | 82.24M | 100.03M | 103.54M | 80.75M |
| Depreciation & Amortization | 15.39M | 20.07M | 19.98M | 19.19M | 18.33M |
| EBITDA | 9.01M | (610K) | 24.65M | 23.9M | 30.22M |
| EBITDA Margin | 3.4% | -0.2% | 6.6% | 6.5% | 8.2% |
| Operating Income | (3.31M) | (21.94M) | 4.67M | 4.53M | 11.88M |
| Operating Margin | -1.3% | -5.7% | 1.3% | 1.2% | 3.2% |
| Interest Income | 58K | 278K | 1.26M | 63K | 161K |
| Interest Expense | 17.35M | 15.22M | 14.27M | 9.18M | 6.84M |
| Other Income / Expenses | (20.43M) | (13.95M) | (14.27M) | (8.99M) | (8.53M) |
| Income Before Tax | (23.74M) | (35.9M) | (9.6M) | (4.47M) | 3.35M |
| Pre-Tax Margin | -9.0% | -9.4% | -2.6% | -1.2% | 0.9% |
| Income Tax Expense | (1.01M) | (1.54M) | (4.19M) | 32K | (22.77M) |
| Net Income | (22.73M) | (34.35M) | (5.41M) | (4.5M) | 26.13M |
| Net Margin | -8.7% | -9.0% | -1.5% | -1.2% | 7.1% |
| EPS (Basic) | (0.65) | (0.72) | (0.09) | (0.07) | 0.42 |
| EPS (Diluted) | (0.65) | (0.72) | (0.09) | (0.07) | 0.41 |
| Weighted Avg Shares | 34.86M | 47.6M | 57.35M | 60.25M | 62.73M |
| Weighted Avg Shares (Diluted) | 34.86M | 47.6M | 57.35M | 60.25M | 64.49M |
CareRx Corporation
TSX:CRRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.